BLA 761063 · Eli Lilly and CO
Emgality
Galcanezumab-Gnlm · Injection
NovelBreakthrough therapyLast checked: Nov 20, 2026Latest source record: Jun 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Sep 27, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
32
12 Phase 3, 5 recruiting
FAERS reports
32,317
4,007 serious, 89 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 5, 2026.
EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 ) 1.1 Migraine EMGALITY is indicated for the preventive treatment of migraine in adults. 1.2 Episodic Cluster Headache EMGALITY is indicated for the treatment of episodic cluster headache in adults.
Mechanism: Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 4, 2019 Supplement 3 · Efficacy · priority review Breakthrough therapyLabelLetter
- Sep 27, 2018 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- EMGALITY · GALCANEZUMAB-GNLM 120MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Galcanezumab" as an intervention, any sponsor and status, largest first.
- Evaluation of Galcanezumab in the Prevention of Chronic MigrainePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT02614261 · 1,117 participants · Start Nov 30, 2015 · Primary completion Mar 16, 2017
Drug: Galcanezumab; Placebo · For: Chronic Migraine
Sites: Phoenix, Arizona; Encino, California; Fullerton, California · 117 sites in all
- Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 StudyPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT02614196 · 986 participants · Start Dec 4, 2015 · Primary completion Mar 29, 2017
Drug: Galcanezumab; Placebo · For: Migraine
Sites: Phoenix, Arizona; Apple Valley, California; Los Angeles, California · 113 sites in all
- Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 StudyPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT02614183 · 862 participants · Start Nov 30, 2015 · Primary completion Mar 22, 2017
Drug: Galcanezumab; Placebo · For: Migraine
Sites: Tucson, Arizona; Little Rock, Arkansas; Carmichael, California · 95 sites in all
- A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic MigrainePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05127486 · 580 participants · Start Dec 6, 2021 · Primary completion May 23, 2023
Drug: Galcanezumab; Rimegepant and 2 more · For: Migraine; Episodic Migraine
Sites: Gilbert, Arizona; Phoenix, Arizona; Tempe, Arizona · 77 sites in all
- A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigrainePivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT03432286 · 533 participants · Start Mar 14, 2018 · Primary completion Nov 14, 2025
Drug: Galcanezumab; Placebo · For: Episodic Migraine
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 73 sites in all
- A Study of Galcanezumab (LY2951742) in Participants With Episodic MigrainePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03963232 · 520 participants · Start Jul 30, 2019 · Primary completion Jul 27, 2021
Drug: Galcanezumab; Placebo · For: Episodic Migraine
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 40 sites in all
- A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant MigrainePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03559257 · 463 participants · Start Jul 31, 2018 · Primary completion Jun 19, 2019
Drug: Galcanezumab; Placebo · For: Migraine
Sites: Phoenix, Arizona; San Diego, California; Ocoee, Florida · 69 sites in all
- A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic MigrainePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT02959177 · 459 participants · Start Nov 9, 2016 · Primary completion Jan 18, 2019
Drug: Galcanezumab; Placebo · For: Migraine
Sites: Chiba, Japan; Chofu-shi, Japan; Fukui, Japan · 47 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site pain7,789
- migraine3,158
- underdose2,919
- headache2,509
- drug ineffective1,980
- product dose omission issue1,766
- injection site haemorrhage1,666
- incorrect dose administered1,197
- injection site erythema1,145
- accidental underdose1,068
- nausea852
- injection site swelling827
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 140 |
| 2019 | 4,657 |
| 2020 | 6,640 |
| 2021 | 4,645 |
| 2022 | 3,737 |
| 2023 | 2,977 |
| 2024 | 3,150 |
| 2025 | 3,672 |
| 2026 | 2,685 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acute and preventive treatment of menstrual migraine: a meta-analysis.
Khoo CC, Liu CC, Lu M, et al. · J Headache Pain 2024 · Meta-Analysis
- Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.
Pringsheim T, Smith DB, Tanveer S, et al. · Neurology 2026 · Systematic Review
- Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
Haghdoost F, Puledda F, Garcia-Azorin D, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
- Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
Detke HC, Goadsby PJ, Wang S, et al. · Neurology 2018 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
Messina R, Huessler EM, Puledda F, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.
Sacco S, Amin FM, Ashina M, et al. · J Headache Pain 2022 · Systematic Review, Practice Guideline
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.